Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach

Rhys Jones, Amaran Krishnan, Gemma L. Zeybel, Emily Dookun, Jeffrey P. Pearson, A. John Simpson, S. Michael Griffin, Chris Ward, Ian A. Forrest
ERJ Open Research 2018 4: 00051-2018; DOI: 10.1183/23120541.00051-2018
Rhys Jones
1Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
5Joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amaran Krishnan
1Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
5Joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gemma L. Zeybel
2Institute of Cell and Molecular Biosciences, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Dookun
2Institute of Cell and Molecular Biosciences, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey P. Pearson
2Institute of Cell and Molecular Biosciences, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. John Simpson
3Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Michael Griffin
1Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Ward
2Institute of Cell and Molecular Biosciences, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
3Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
6Joint senior authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chris Ward
Ian A. Forrest
4Dept of Respiratory Medicine, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
6Joint senior authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ian.forrest@nuth.nhs.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

After MDT work-up and review, gastro-oesophageal reflux and pulmonary aspiration were found to be common in IPF patients; surgery was recommended in only 10% http://ow.ly/rO3T30lU17o

To the Editor:

Despite recent therapeutic advances, the prognosis for patients with idiopathic pulmonary fibrosis (IPF) remains poor. The link with gastro-oesophageal reflux disease (GORD) has been identified as a research priority, as GORD appears to be common in IPF and may be associated with adverse outcomes [1]. GORD is often clinically silent in IPF, so detection is challenging [2].

Traditionally, measurement of reflux has relied on oesophageal pH probes. Newer probes can demonstrate weakly acid and non-acid reflux through changes in electrical conductivity. Bronchoalveolar lavage fluid (BALF) has been used to provide evidence of aspiration through the detection of gastrointestinal markers [3].

We undertook a pilot study to investigate whether pH-impedance and BALF studies could be combined to assess reflux and aspiration in IPF. We developed a novel “aerodigestive” multidisciplinary team (MDT) approach to support personalised treatment in clinical practice.

Ethical approval was obtained for a prospective observational study (10/H0908/8). Patients diagnosed with IPF according to European Respiratory Society/American Thoracic Society [4] criteria were recruited from the regional interstitial lung disease clinic.

Participants completed the reflux symptom index (RSI), a validated nine-item questionnaire [5]. RSI scores >13 are abnormal. For patients taking proton pump inhibitors (PPI), questionnaires were repeated after 2 weeks off therapy, prior to oesophageal physiology and bronchoscopy.

Oesophageal manometry was performed using a water-perfused catheter (MMS, Enschede, the Netherlands). During the study, eight-channel equipment was upgraded to 20-channel high-resolution manometry (HRM). Oesophageal peristalsis and lower oesophageal sphincter function were assessed using established protocols [6, 7]. The location of the lower oesophageal sphincter was manometrically defined. 24-h ambulatory pH impedance monitoring was performed using the Ohmega system (MMS). Data were compared to normal ranges in healthy volunteers [8]. The DeMeester score was used as a composite evaluation of distal pH [2].

Bronchoscopy and lavage were performed to a standardised protocol by a single clinician (IAF). The bronchoscope was wedged in the right middle lobe and 3×60 mL normal saline instilled. Cell-free BALF supernatants were prepared by centrifugation at 183×g for 6 min at 4°C and stored at −80°C for later analysis.

We used a validated, in-house, indirect pepsin ELISA. A monospecific antibody to porcine pepsin was used to measure pepsin and total pepsinogens [9]. Four healthy volunteers recruited from university staff provided BALF samples as controls. We used a spectrophotometric assay to measure total bile acid concentrations (TBA kit; Alere, Stockport, UK).

After spirometry and high-resolution thoracic computed tomography, patients were reviewed in a formal aerodigestive MDT comprising oesophagogastric surgeons, respiratory physicians and anaesthetists.

Statistical analysis was performed using Minitab 16 (DataONE, Albuquerque, NM, USA).

79 patients were screened as eligible and invited to participate. 36 patients (27 male) completed all study investigations (October 2010 to June 2014) (figure 1a). Median age was 73 years. 11 patients had previous evidence of GORD, either documented in clinical letters or visualised at endoscopy. Regular medications included PPI (n=25), prednisolone (n=10; 2.5–10 mg dose range) and N-acetylcysteine (n=8). Subgroup analysis by medication revealed no effect on reflux or aspiration.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

a) Flowchart of study recruitment and participation; b) concentrations of pepsin measured in bronchoalveolar lavage fluid from healthy volunteer controls and idiopathic pulmonary fibrosis (IPF) study patients. Study patients with high DeMeester scores (pH assessment) or supranormal total reflux events (impedance assessment) are indicated as IPF+GOR (gastro-oesophageal reflux disease).

Median (range) forced expiratory volume in 1 s FEV1 was 2.2 (1.4–3.6) L. Median FEV1 was 83.5 (46.8–163.6)% predicted. Median vital capacity was 2.6 (range 1.5–4.7) L. Median vital capacity was 77.6 (47.9–146.4)% pred.

The median RSI score for the patients taking PPI was 11 (0–32). The median score off-PPI was 10 (0–39). RSI scores did not correlate with levels of proximal reflux and the effect of PPI withdrawal was inconsistent.

11 patients underwent eight-channel manometry and the remainder underwent HRM. Within the two groups, abnormal physiology was reported in five (45%) and 15 (60%) patients, respectively. The majority of abnormal tests were consistent with ineffective oesophageal motility (eight-channel) or weak peristalsis (HRM).

All but one subject discontinued PPI therapy. 20 (56%) patients had a high DeMeester score or prolonged oesophageal acid exposure. In nine patients, impedance analysis revealed high levels of reflux (total, acid or weakly acid). Five of these nine patients had normal pH traces. Three (20%) patients had abnormal proximal oesophageal reflux. Overall, 22 (61%) patients had a high DeMeester score, a high total number of impedance reflux events or both.

17 (44%) of the 36 study subjects had pepsin concentrations above the levels recorded in the control population (control range 0–2.3 ng·mL−1) (figure 1b). The values for these positive readings ranged from 7 to 44 ng·mL−1. Using the TBA assay, only four out of 36 subjects had detectable levels of bile acids.

In the majority of patients with pathological reflux on ambulatory monitoring, the MDT recommended medical therapy. Lack of fitness for surgery was the commonest reason to recommend against fundoplication. Evidence of reflux from additional investigations was also considered. Antireflux surgery was recommended for three patients; two underwent surgery and the third declined.

We have demonstrated the safety and feasibility of an integrated assessment of gastro-oesophageal reflux and aspiration in an unselected, real-world sample of IPF patients. The pattern of study recruitment helps to illustrate the burden of these invasive tests.

Approximately half of our patients had abnormal levels of reflux at ambulatory monitoring. Our data contrast with higher rates reported previously by Raghu et al. [10] and Savarino et al. [11] (87% and 83%, respectively). As in previous reports, clinically silent reflux was common [2]. Reflux symptoms were easier to detect with the use of a structured questionnaire.

The study by Savarino et al. [11] is the first to evaluate BALF and saliva/sputum samples from IPF patients for total bile acids. The commercial assay used (Bio-Quant, San Diego, CA, USA) assumes an accurate detection of levels <1 umol·L−1. The authors concluded that patients with IPF had more bile acids in BALF and saliva than non-IPF patients and controls.

In the current study we used an alternative colorimetric assay, for which we have previously reported superior sensitivity [12]. Only three patients had measurable levels of bile salts and only one of these had readings >5 μmol·L−1. Results from our group and others indicate that colorimetric detection of levels <5 μmol·L−1 may be unreliable [12, 13]. Overall, we conclude that levels of bile acids were not raised in our patients.

We found elevated levels of pepsin in BALF, indicating that gastric aspiration may occur. This is concordant with the findings of Savarino et al. [11] and Lee et al. [14]. Further studies regarding markers of aspiration including pepsin are indicated.

Our study participants had high levels of oesophageal dysfunction at manometry. This may relate to their age, as reference ranges were derived from younger subjects and peristalsis weakens with age [8]. Alternatively, a link between dysmotility and IPF has been suggested [2]. Significant oesophageal hypomotility can compromise swallowing after fundoplication. Detection is mandatory for operative planning and patient consent.

At present, the IPF literature suggests high levels of reflux disease and supports a benefit of antireflux therapy, including fundoplication, for lung health [10, 11, 14, 15]. Randomised data are awaited. As we learn how best to measure reflux and aspiration in IPF, it is crucial that the risks of surgery in the IPF population are accurately represented. In our institution, after formal MDT review, fundoplication was only recommended for a minority of IPF patients. Antireflux surgery may be appropriate in selected cases, but careful consideration is required in a group of patients who are often elderly with multiple comorbidities.

Footnotes

  • Conflict of interest: None declared.

  • Support statement: This work was jointly funded by Innovate UK and the Northern Oesophago-Gastric Fund. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received April 4, 2018.
  • Accepted September 11, 2018.
  • Copyright ©ERS 2018

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. NICE
    . CG163 Idiopathic Pulmonary Fibrosis: NICE Guidance. National Institute of Clinical Excellence, 2013.
  2. ↵
    1. D'Ovidio F,
    2. Singer LG,
    3. Hadjiliadis D, et al.
    Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80: 1254–1260.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Meyer KC,
    2. Raghu G,
    3. Baughman RP, et al.
    An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185: 1004–1014.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Joint ATS/ERS Working Group
    . American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646–664.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Belafsky PC,
    2. Postma GN,
    3. Koufman JA
    . Validity and reliability of the reflux symptom index (RSI). J Voice 2002; 16: 274–277.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bredenoord AJ,
    2. Fox M,
    3. Kahrilas PJ, et al.
    Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012; 24: Suppl. 1, 57–65.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Spechler SJ,
    2. Castell DO
    . Classification of oesophageal motility abnormalities. Gut 2001; 49: 145–151.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Zerbib F,
    2. des Varannes SB,
    3. Roman S, et al.
    Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005; 22: 1011–1021.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Stovold R,
    2. Forrest IA,
    3. Corris PA, et al.
    Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection. Am J Respir Crit Care Med 2007; 175: 1298–1303.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Raghu G,
    2. Freudenberger TD,
    3. Yang S, et al.
    High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136–142.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Savarino E,
    2. Carbone R,
    3. Marabotto E, et al.
    Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013; 42: 1322–1331.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Parikh S,
    2. Brownlee IA,
    3. Robertson AG, et al.
    Are the enzymatic methods currently being used to measure bronchoalveolar lavage bile salt levels fit for purpose? J Heart Lung Transplant 2013; 32: 418–423.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Klokkenburg JJ,
    2. Hoeve HL,
    3. Francke J, et al.
    Bile acids identified in middle ear effusions of children with otitis media with effusion. Laryngoscope 2009; 119: 396–400.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Lee JS,
    2. Song JW,
    3. Wolters PJ, et al.
    Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 352–358.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Allaix ME,
    2. Fisichella PM,
    3. Noth I, et al.
    Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment. J Gastrointest Surg 2014; 18: 100–104.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 4 Issue 4 Table of Contents
ERJ Open Research: 4 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach
Rhys Jones, Amaran Krishnan, Gemma L. Zeybel, Emily Dookun, Jeffrey P. Pearson, A. John Simpson, S. Michael Griffin, Chris Ward, Ian A. Forrest
ERJ Open Research Oct 2018, 4 (4) 00051-2018; DOI: 10.1183/23120541.00051-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach
Rhys Jones, Amaran Krishnan, Gemma L. Zeybel, Emily Dookun, Jeffrey P. Pearson, A. John Simpson, S. Michael Griffin, Chris Ward, Ian A. Forrest
ERJ Open Research Oct 2018, 4 (4) 00051-2018; DOI: 10.1183/23120541.00051-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • rs2070600 SNP regulates AGER splicing and sputum sRAGE
  • Procoagulant microparticles and COVID-19
  • Cancer referral and interventional pulmonology during COVID-19
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society